Avatrombopag maleate - CAS 677007-74-8

Avatrombopag, also known as AKR-501, YM477, AS 1670542 or E5501, is a novel orally-active thrombopoietin (TPO) receptor agonist. AKR-501 specifically targeted the TPO receptor and stimulated megakaryocytopoiesis throughout the development and maturation of megakaryocytes just as rhTPO did. AKR-501 may be useful in the treatment of patients with thrombocytopenia. Avatrombopag was first approved in 2018.

STAT, ERK, Cytochromes P450, Others, Thrombopoietin Receptor

JAK/STAT signaling, Metabolism, Stem Cells, MAPK, Others, Immunology/Inflammation

676925

C33H38Cl2N6O7S2

765.72

OC(=O)\C=C/C(O)=O.OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1nc(-c2cc(Cl)cs2)c(s1)N1CCN(CC1)C1CCCCC1

-20°C

Ice Packs

Small Compound